C. Barfield, "Anti-GD2 antibody therapy for GD2-expressing tumors," Current Cancer Drug Targets, vol. 10, no. 2, pp. 200-209, 2010.Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2- expressing tumors. Curr Cancer Drug Targets 2010;10:200-9....
Safe anti-GD2 cancer immunotherapies targeting O-acetylated-GD2 OGD2 Pharma publishes new data on glioblastoma antibody therapy Researchers from Taiwan and California, directed by Pr. Alice Yu, have published new data showing that OAcGD2 is a novel marker for breast cancer stem cells, the rare su...
Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. He...
Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 120, 548–554 (2014). Article CAS PubMed Google Scholar Gibson, T. M. et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–...
Due to its limited expression on normal tissue, the GD2 disialogangloside expressed on neuroblastoma cells is an excellent candidate for mAb therapy. In 2015, dinutuximab (an anti-GD2 mAb) was approved by the US FDA and is currently used in a combination immunotherapeutic regimen for the ...
et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013). Article CAS PubMed Google Scholar Keshelava, N. et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant...
(cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide, with or without topotecan, vincristine, and doxorubicin), had achieved a disease response that fulfilled prespecified criteria, had received high-dose therapy (busulfan and melphalan or carboplatin, etoposide, and melphalan) and had ...
P. et al. Characterization of human neuroblastoma cell lines established before and after therapy. J. Natl. Cancer Inst. 76, 375–387 (1986). CAS PubMed Google Scholar Boonstra, M. C. et al. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating ...
Patient cells were manufactured in the cGMP facility of the Center for Cell and Gene Therapy at Texas Children’s Hospital and evaluated using multi-color flow cytometry. a, NKT frequency (CD3+iNKT+) in initial apheresis product for the three patients. b, NKT purity and CAR expression at the...
The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a ...